标题
MDM2 inhibition: an important step forward in cancer therapy
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-10
DOI
10.1038/s41375-020-0949-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy
- (2020) Naval G. Daver et al. BLOOD
- MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
- (2020) Pau Montesinos et al. Future Oncology
- A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
- (2020) Qiuyun Luo et al. ONCOLOGY RESEARCH
- A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
- (2019) Lukasz Skalniak et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
- (2019) Drew W. Rasco et al. JOURNAL OF CLINICAL ONCOLOGY
- MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
- (2019) Arushi Khurana et al. OncoTargets and Therapy
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
- (2019) W. Larry Gluck et al. INVESTIGATIONAL NEW DRUGS
- MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
- (2019) Douglas D. Fang et al. Journal for ImmunoTherapy of Cancer
- Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
- (2018) John Nemunaitis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
- (2018) Jo Ishizawa et al. CANCER RESEARCH
- Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer
- (2018) Dorothea Rudolph et al. CANCER RESEARCH
- Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers
- (2018) Hui Qin Wang et al. CANCER RESEARCH
- Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma
- (2018) Albiruni Abdul Razak et al. CANCER RESEARCH
- Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic
- (2018) Joerg Rinnenthal et al. CANCER RESEARCH
- Abstract 314: A novel MDM2-p53 antagonist APG-115 induces p53-mediated apoptosis and enhances radiosensitivity in colorectal cancer
- (2018) Han-Jie Yi et al. CANCER RESEARCH
- Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules
- (2018) Dorothea Rudolph et al. CANCER RESEARCH
- A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
- (2018) Todd Michael Bauer et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4 inhibition diminishes p53 activation by MDM2 antagonists
- (2018) Anusha Sriraman et al. Cell Death & Disease
- Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
- (2018) Vikas Dembla et al. Oncotarget
- Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
- (2018) Anne Berberich et al. CLINICAL CANCER RESEARCH
- High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia
- (2017) Zhihong Zeng et al. HAEMATOLOGICA
- Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
- (2017) Audrey Laroche-Clary et al. Journal of Hematology & Oncology
- Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
- (2017) Angelo Aguilar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma
- (2017) Frank Herting et al. LEUKEMIA & LYMPHOMA
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
- (2017) Viktor Arnhold et al. Oncotarget
- MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
- (2017) Audrey Laroche et al. Oncotarget
- High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia
- (2017) Zhihong Zeng et al. HAEMATOLOGICA
- The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
- (2016) Andreas C. Joerger et al. Annual Review of Biochemistry
- The Roles of MDM2 and MDMX in Cancer
- (2016) Orit Karni-Schmidt et al. Annual Review of Pathology-Mechanisms of Disease
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
- (2016) D. Chiron et al. BLOOD
- Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials
- (2016) Stéphane Ferretti et al. CANCER RESEARCH
- Abstract 1239: NVP-HDM201: Biochemical and biophysical profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2
- (2016) Thérèse Stachyra-Valat et al. CANCER RESEARCH
- Abstract 3761: The MDM2 inhibitor AMG 232 causes tumor regression and potentiates the anti-tumor activity of MEK inhibition and DNA-damaging cytotoxic agents in preclinical models of acute myeloid leukemia
- (2016) Jude R. Canon et al. CANCER RESEARCH
- Abstract 1225: NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2
- (2016) Sébastien Jeay et al. CANCER RESEARCH
- Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
- (2016) Frank Herting et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
- (2016) Christian Lehmann et al. Journal of Hematology & Oncology
- p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status
- (2016) A Quintás-Cardama et al. LEUKEMIA
- Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
- (2016) Yu Liu et al. NATURE
- P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
- (2016) Emna Mahfoudhi et al. Oncotarget
- Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
- (2016) Guillaume Carita et al. Oncotarget
- Clinical Overview of MDM2/X-Targeted Therapies
- (2016) Andrew Burgess et al. Frontiers in Oncology
- Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53–MDM2 interaction with a distinct binding mode
- (2015) François Gessier et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract 1614: Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
- (2015) Peter J. Houghton et al. CANCER RESEARCH
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
- (2015) C. G. Hoffman-Luca et al. CLINICAL CANCER RESEARCH
- Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
- (2015) Philipp Holzer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors
- (2015) L. R. Werner et al. MOLECULAR CANCER THERAPEUTICS
- The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
- (2015) J. Canon et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
- (2015) Bing Z. Carter et al. Oncotarget
- Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
- (2015) Lindi Chen et al. Oncotarget
- Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial
- (2015) Sebastien Jeay et al. CANCER RESEARCH
- Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma
- (2015) Hui Qin Wang et al. CANCER RESEARCH
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon 2a target JAK2V617F-positive progenitor and stem cells
- (2014) M. Lu et al. BLOOD
- Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
- (2014) B. Higgins et al. CLINICAL CANCER RESEARCH
- Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
- (2014) Daqing Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abstract B55: Antitumor activity of the MDM2 antagonist RG7388.
- (2014) B. Higgins et al. MOLECULAR CANCER THERAPEUTICS
- Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
- (2013) Camelia Iancu-Rubin et al. EXPERIMENTAL HEMATOLOGY
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- 2a specifically targets JAK2V617F-positive polycythemia vera cells
- (2012) M. Lu et al. BLOOD
- The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
- (2012) V. Pant et al. BLOOD
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim
- (2010) W. Zhang et al. CANCER RESEARCH
- Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
- (2010) Min Lu et al. EXPERIMENTAL HEMATOLOGY
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
- (2008) Sanjeev Shangary et al. Annual Review of Pharmacology and Toxicology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now